Details for Patent: 8,920,838

Title:	Delayed-release glucocorticoid treatment of rheumatoid disease
Abstract:	Provided are methods for the treatment of a rheumatic disease, such as rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatic, by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks. Also provided are methods for the treatment of osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks.
Inventor(s):	Schaeffler; Achim (Beerfelden, DE)
Assignee:	Horizon Pharma AG (Reinach, CH)
Filing Date:	Apr 10, 2013
Application Number:	13/860,015
Claims:	1. A method for the treatment of a patient suffering from signs and symptoms of an underlying rheumatic disease and/or osteoarthritis, which comprises administering to said patient an effective amount of prednisone contained in a delayed-release dosage form, wherein said treatment is administered once daily for at least about two weeks, wherein said patient has previously undergone treatment with an oral immediate release dosage form of a glucocorticoid and was refractory to said treatment with said oral immediate release dosage form of a glucocorticoid, and wherein the delayed release dosage form is a tablet or a capsule. 2. The method of claim 1, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form for at least about four weeks. 3. The method of claim 2, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form for at least about eight weeks. 4. The method of claim 3, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form one for at least about twelve weeks. 5. The method of claim 4, wherein the treatment comprises administration of the prednisone contained in a delayed-release dosage form for at least about twelve months. 6. The method of claim 1, wherein the rheumatic disease is rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatica. 7. The method of claim 1, wherein the delayed-release dosage form has a lag time of from about 2 hours to about 6 hours after administration. 8. The method of claim 1, wherein the delayed-release dosage form has a lag time of from about 3 hours to about 5 hours after administration. 9. The method of claim 1, wherein the delayed-release dosage form has a dissolution time of equal to or less than about 2 hours after the lag time is reached. 10. The method of claim 1, wherein the delayed-release dosage form has a drug release behaviour which is independent of pH.